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Thomas C. SheaIncluded in this issue is an article by Freytes et al. unrelated donors (90% of the population), and the
[1] describing a Center for International Blood and
Marrow Transplant Research analysis of 263 patients
with mantle cell, large cell, or follicular lymphoma
who underwent a reduced intensity allogeneic
transplantation at the time of progression after a
prior autologous transplantation. This analysis
describes the relapse rates, non-relapse mortality,
progression-free, and overall survival of these patients
out to 5 years. Twenty-five percent of the patients re-
mained alive 5 years after their second transplanta-
tion with no significant difference in outcomes
among the 3 disease categories. Only 17% of patients
remained progression-free at that time with a treat-
ment-related mortality rate of 30% at day 100 and
44% by the end of 5 years. Risk factors for death
or relapse included a Karnofsky performance score
less than 90%, an interval of less than 24 months be-
tween the autologous and allogeneic transplantation,
not using total body irradiation (TBI) in the trans-
plantation conditioning regimen, and primary refrac-
tory or chemotherapy refractory disease before
allogeneic transplantation. Patients with all of these
risk factors had an 8.3-fold increase of relapse or
treatment-related mortality compared with those
with none of these risk factors. Karnofsky perfor-
mance score, time between transplantations, and use
of TBI conditioning were the strongest predictors
of outcome.
Although the relapse rates in this study were ap-
proximately 10% higher than those for a group of
patients with large cell lymphoma recently reported
by van Kampen et al. [2], the biggest contributor to
the poor outcomes in the current analysis was the
high nonrelapse mortality. This is substantially greater
than that reported in other series of second transplan-
tations and may be attributable to the large number ofUNC Lineberger Comprehensive Cancer Center and
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third of the total population). Unfortunately, no sepa-
rate analyses on the outcome of these poorly matched
patients or according to different numbers of risk fac-
tors are provided, so their individual effects are hard to
quantify.
So what else can we learn from this analysis that
will inform our decisions in the future? It would
seem that the most important question is that given
the outcomes described, would this population have
done better if they were to undergo allogeneic trans-
plantation in first remission rather than waiting for
progression? Large series that have looked at the re-
sults of allogeneic transplantation for large cell lym-
phoma have not identified a population of patients
that would do better with an allogeneic rather than
an autologous transplantation, although there is
a hint that high-risk patients did better than expected
with allografts as compared to their projected outcome
with an autologous approach as initial therapy for
recurrent or refractory disease [3]. Given the high
relapse rates reported in the CORAL trial [4] for
patients who recur quickly after initial chemotherapy,
particularly if they failed a rituximab-containing regi-
men, perhaps an allograft in this patient population
would be more effective than an autologous approach.
It is however, speculation as to whether this would be
the case, particularly given the difficulty in finding
appropriate matches quickly enough to benefit
patients with rapidly progressive non-Hodgkin lym-
phoma (NHL).
In contrast to the paradigm of therapy for patients
with large cell NHL, patients with mantle cell lym-
phoma are frequently treated with very aggressive
induction regimens such as rituximab plus hyper-
cyclophosphamide, vincristine, adriamycin, dexameth-
asone or abbreviated but intensive induction regimens
followed by autotransplantation as part of their initial
therapy. Data from a number of reports suggest
approximately a 50% 5-year progression-free survival
with these approaches [5,6]. Other reports have
suggested better outcomes than that outlined in this
study for patients with mantle cell lymphoma when
treated with allogeneic transplantation after an initial
relapse, but none of them are large enough to dictate
standard of care [7].
Biol Blood Marrow Transplant 18:1145-1149, 2012 1149The Bottom LineLong-term follow-up of autologous transplanta-
tions early in the course of follicular lymphoma
therapy are encouraging, but most studies suggest
a high relapse rate over time and significant incidence
of treatment-related myelodysplastic syndrome or
acute myelogenous leukemia [8]. These results have
dampened the enthusiasm of many investigators for
early autologous transplantation in this patient group,
especially when less morbid alternatives are available.
Last, it is worth noting that a number of phase II
reports including a CALGB series have suggested
that allogeneic transplantation for aggressive follicular
lymphoma can lead to a 60% to 75% disease-free
survival with follow-ups as long as 10 years by some
groups [9,10]. Although those results do not include
patients who have failed an autologous transplan-
tation, they include patients that have usually failed
initial therapy and underwent transplantation in
second or subsequent remission. Whether selection
biases such as excluding patients who failed prior
autologous transplantations have led to better
outcomes in those studies, those prospective trial
results are nevertheless strikingly better than that
described in the current registry analysis. More
recently, spectacular results were provided by Cohen
et al. [11] who reported a 96% disease-free survival
and progression-free survival with a 39-month
follow-up in 27 patients who were treated with
a planned tandem autologous transplantation followed
by allogeneic transplantation as part of their initial
therapy for follicular lymphoma. The results of this
small nonrandomized trial are remarkable and suggest
that earlier use of allogeneic transplantation after
a planned autologous transplantation could lead to bet-
ter outcomes than the use of allogeneic transplanta-
tions as salvage therapy after a failed autologous
transplantation. Regardless of the interpretation of
the Cohen et al. [11] study, the late use of allogeneic
transplantations in patients with advanced disease
seems ill-advised given the high mortality and relapse
rates reported here.
Where then, does this report leave us? Aside from
encouraging the use of low-dose TBI in the condi-
tioning regimen and, in my opinion, use of earlier
allografts in follicular NHL, I do not see these results
changing our practice a great deal. Whether you con-
sider the outcomes here to represent a glass half-full or
half-empty, the use of salvage allografts after relapse
after an autograft transplantation are helpful for only
a handful of patients with NHL, especially for those
with the poor prognostic factors described in this
report. Perhaps the more judicious use of salvage allo-grafts in those with fewer risk factors and greater use
of low-dose TBI will lead to better outcomes, but
more often than not, these factors are beyond the
control of both the patient and their physician and if
we do not succeed the first time, leave us to try and
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